British Journal ofPsychiatry (1995) , 167, 480â€"482 The adverse effects of antipsychotic drugs continue to be a major problem in the management of schizophrenia and an important reason for non compliance (van Putten, 1974) , which in turn undermines the successful management of schizophrenic patients. One of the commonest adverse effects is akathisia, which has been associated with suicide and violent behaviour (van Putten, 1974; Drake & Ehrlich, 1985) . An important aspect of the akathisia syndrome, dysphoria (a subjective, unpleasant mood) (Halstead eta!, 1994) , is, however, often unrecognised (van Putten, 1975) . Therefore, patients who are irritable or complain of tension or panic can be given excessive treatment rather than dose reduction.
Dysphoria has long been recognised in non psychotic subjects given antipsychotic drugs (Hollister, 1992) , and indeed one such report (Anderson et a!, 1981) was influential in deterring many investigators from the use of antipsychotic drugs in normal, healthy volunteer studies. This was partly due to the long duration of adverse effects described in three subjects who allegedly had symptoms which persisted for up to 6 weeks. This was an unfortunate consequence since such studies are important in order to delineate the neuro psychological, cognitive and psychomotor effects of these drugs from the psychopathological effects of illness in patients. We therefore report our experience in a large series of volunteers given haloperidol.
Method
In a pharmacokinetic study of haloperidol, we gave two groups of healthy volunteers (26 and 25 subjects; 51 in total) a single, oral dose of haloperidol 5 mg on two separate days. The total drop-out rate of 40â€"50% was largely due to adverse effects (Table 1) . These were most frequently subjective complaints of dysphoria or agitation, while objective signs of akathisia (motor restlessness) were much less evident.
Results
Every subject who dropped out was examined by the principal investigator (DJK) who was experienced in diagnosing akathisia in psychiatric patients. Since the principal aim of the study was an investigation of pharmacokinetic variables, no formal rating scales for adverse drug reactions were used. As shown in Table 1 , however, the investigator's index of suspicion for akathisia was markedly increased on the second study day. This was because a similar number of drop-outs due to identical subjective complaints began to be made after a similar 3-hour time interval after dosing to the first study day. here,;. . I need to go home.. . I'll be all right outside
In the first group of 26 subjects, the drop-out times ranged from 3â€"8 hours after dosing. When these similar events occurred in the second group of 25 subjects, procycidine 10 mg was given intravenously to all ten subjects with subjective dysphoria, regardless of the presence or absence of objective signs of restlessness. Seven of these had a good response and two were euphoric (â€oeThat's wonderful stuff. . . what's it called? . . . where can you get it?â€•). All dysphoric symptoms resolved completely within 2â€"3 hours. This was in marked contrast to the report by Anderson eta! (1981) in which two of the three subjects were not helped bydiphenhydramine or benztropine.
Discussion
The importance of this study was the similarity in the nature of the subjective dysphoric complaints to those frequently heard from psychiatric patients given antipsychotic drugs; the response to anticholinergic medication; and the fact that subjective dysphoria can occur as an important adverse effect in the absence of objective signs of akathisia.
We have also reported dose-dependent effects of haloperidol (2, 4 and 6 mg) on eye movements in healthy volunteers which were maximal at 4 mg (King, 1994) . This is remarkably similar to the average â€˜¿ neuroleptic threshold' of 3.7 mg found in schizophrenic patients (McEvoy et a!, 1991) . Thus the widely held view that patients can tolerate much greater doses of neuroleptic drugs than normal healthy subjects (Young et al, 1994 )may be fallacious and based on an erroneous comparison between the effects of acute and chronic dosing.
Dysphoria has recently been identified as a major factor in the residual psychopathology and poor treatment response in psychotic patients on antipsychotic drugs (Newcomer eta!,1994) . This should be distinguished from any underlying depressive or other mood disturbances associated with the illness itself.
Although Young et al's (1994) report suggests that antidepressant medication may be beneficial, there might be a reciprocal impairment of antipsychotic efficacy (Kramer et a!, 1989) . Following an earlier demonstration that anticholinergic medication antagonised the antipsychotic effect of flupenthixol (Johnstone eta!, 1983) , it has been customary in the UK, and indeed backed up by a World Health Organization Consensus Statement (1990) , to avoid the adjunctive use of anticholinergic drugs if possible. On the other hand, on the basis of their findings in an Italian study, Spina et a! (1993) have recommended short-term anticholinergic prophylaxis for patients beingtreated with high potency antipsychotic drugs. Our experience also suggests that anticholinergic drugs wouldbeeffective in the immediate or acute situation. Nevertheless, further, properly designed, placebo-controlled studies will be required to establish whether this is due to a direct effect on dysphoric mood or a non-specific stimulant effect.
Compliance with antipsychotic medication could certainly be improved if dysphoric reactions were detected and effectively treated more often. 
